Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

UBS Asset Management

Investor type Private Equity Firm


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 8
Average round size
The average size of a deal this fund participated in
Portfolio companies 5
Lead investments 1
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 2
Key employees 1

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Life Science

The main office of represented Corporate Investor is situated in the London. The company was established in Europe in United Kingdom.

The higher amount of exits for fund were in 2019. The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is generally included in less than 2 deals every year. Opposing the other organizations, this UBS Asset Management works on 11 percentage points more the average amount of lead investments. The top activity for fund was in 2016.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the UBS Asset Management, startups are often financed by MPM Capital, Taiho Ventures, New Leaf Venture Partners. The meaningful sponsors for the fund in investment in the same round are MPM Capital, Taiho Ventures, New Leaf Venture Partners. In the next rounds fund is usually obtained by MPM Capital, Taiho Ventures, New Leaf Venture Partners.

Among the most popular portfolio startups of the fund, we may highlight TCR2, Harpoon Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Life Science, Therapeutics.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of UBS Asset Management:
Typical Co-investors
UBS Asset Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after UBS Asset Management:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Altira Group Colorado, Denver, United States
Arix Bioscience England, London, United Kingdom
Edison International California, Rosemead, United States
Estlander & Partners -
[email protected] Boulogne-Billancourt, France, Ile-de-France
Fi Capital Beijing, Beijing, China
Industrial Investment Corporation -
Long Focus Capital -
Modernization and Technology Development Fund -
Mustedanagic & Plott Brothers GbR -
Praktikerinvest Stockholm, Stockholm County, Sweden
Runet Labs Krasnodar, Krasnodar Krai, Russia
Septeni Chiyoda, Japan
Shoutou Zichan China, Guangdong, Zhuhai
Tactics II Stem Cell Ventures Illinois, Northbrook, United States
The Foundry California, Menlo Park, United States
Times Business Solutions Limited -
Zhejiang Chengzhang Wenchuang Zichan China, Hangzhou, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$60M30 Aug 2022 Tustin, California, United States

REEF Technology

E-Commerce Platforms
Food Delivery
Information Technology
Last Mile Transportation
Real Estate
$700M03 Nov 2020 Miami, Florida, United States

Altitude Infrastructure

$590M17 Sep 2020 France, Bourgogne-Franche-Comté, France

Harpoon Therapeutics

Health Care
$70M12 Nov 2018 South San Francisco, California, United States


Health Care
Life Science
$125M21 Mar 2018 Cambridge, Massachusetts, United States

Harpoon Therapeutics

Health Care
$45M25 May 2017 South San Francisco, California, United States


Health Care
Life Science
$44M08 Dec 2016 Cambridge, Massachusetts, United States

Harpoon Therapeutics

Health Care
$15M01 Apr 2016 South San Francisco, California, United States
GOOD Meat, a Division of Eat Just, Inc., Secures $170 Million to Scale Meat Without Slaughter as Demand Grows

– Eat Just, Inc. announced that its GOOD Meat division has secured $170m in new funding.
– With this transaction, GOOD Meat becomes a subsidiary of Eat Just, which announced a $200m fundraise in March.
– The latest investment from funds managed by UBS O’Connor, a hedge fund manager within UBS Asset Management, Graphene Ventures, K3 Ventures and others, will be used to increase capacity and accelerate research and development for high-quality, real meat without slaughter.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent UBS Asset Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: